Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Peptide Based Metabolic Disorders Therapeutics Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The peptide based metabolic disorders therapeutics market has seen swift growth in recent years. It is anticipated to increase from $34.1 billion in 2025 to $39.05 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.5%. This historical growth can be attributed to several factors, including the increasing prevalence of type 2 diabetes, the early successes of liraglutide and exenatide therapies, the growing clinical validation of peptide drugs, rising obesity rates in developed economies, and an improved understanding of metabolic pathways.
The peptide based metabolic disorders therapeutics market is anticipated to experience substantial expansion over the coming years. This market is projected to reach $63.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. This forecasted increase can be attributed to several factors, including the escalating global prevalence of obesity, the growing acceptance of semaglutide and advanced peptides, increased funding for metabolic disorder drug development, the rising need for sustained weight management solutions, and continuous improvements in peptide drug delivery methods. Key developments expected during this period involve a greater uptake of GLP-1 receptor agonist treatments, an intensified focus on managing obesity with peptide-based approaches, the wider availability of long-acting injectable peptide formulations, an increase in combination peptide therapies, and a growing demand for user-friendly metabolic treatments.
Get A Free Sample Report With In-Depth Market Insights:
Peptide Based Metabolic Disorders Therapeutics Market Growth Backed By Core Demand Fundamentals
The increasing incidence of obesity is anticipated to fuel the expansion of the peptide-based metabolic disorders therapeutic market in the future. Obesity is defined as a medical state marked by an excessive build-up of body fat, which presents significant health hazards. The growing number of obesity cases stems from factors such as inactive lifestyles, poor eating habits, genetic factors, and environmental conditions that encourage high-calorie food consumption and a lack of physical movement. Peptide-based therapies for metabolic disorders are designed to address conditions like obesity by utilizing peptides to modulate metabolic processes, enhance insulin responsiveness, and manage hunger, consequently improving patient well-being and mitigating enduring health dangers linked to these persistent conditions. For example, data from December 2024, provided by the Office for Health Improvement and Disparities, a UK-based government department, indicated that from 2022 to 2023, 25.4% of women in early pregnancy were recorded as obese, a figure that saw a slight rise to 26.2% between 2023 and 2024. Consequently, the growing occurrence of obesity serves as a key impetus for the peptide-based metabolic disorder therapeutics market.
Peptide Based Metabolic Disorders Therapeutics Market Segment Outlook: Which Categories Are Growing Fastest?
The peptide based metabolic disorders therapeutics market covered in this report is segmented –
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders
Peptide Based Metabolic Disorders Therapeutics Market Growth Trends Reshaping The Competitive Landscape
Companies operating in the peptide-based metabolic disorders therapeutics market are actively creating innovative peptide-based treatments, such as anti-diabetic biosimilars, to fulfill unmet medical demands and broaden patient treatment possibilities. Peptide-based anti-diabetic biosimilars are therapeutic medications that mirror existing peptide-based diabetes therapies, offering comparable efficacy and safety to established drugs while potentially lowering treatment costs through competitive pricing. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Lirafit, a biosimilar form of the widely used anti-diabetic drug Liraglutide, in India. This medication belongs to the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class. Drugs in this category mimic the natural GLP-1 hormone’s function, which is critical for regulating blood sugar levels. This biosimilar has successfully completed clinical trials, demonstrating its effectiveness in reducing glycemic parameters, promoting weight loss, and enhancing cardiovascular safety. These benefits are crucial for effectively managing diabetes and associated conditions like obesity and cardiovascular diseases.
Peptide Based Metabolic Disorders Therapeutics Market Leading Companies And Competitive Benchmarking
Major companies operating in the peptide based metabolic disorders therapeutics market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Ipsen S.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Amarin Corporation plc
View The Full Peptide Based Metabolic Disorders Therapeutics Market Report:
Peptide Based Metabolic Disorders Therapeutics Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model